Reducing the risk of bone loss associated with breast cancer treatment

Breast

Volumn 16, Issue SUPPL. 3, 2007, Pages 10-15

  Hadji, P ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Aromatase inhibitor; Bisphosphonate; Fracture risk; Osteopenia; Postmenopausal; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; EXEMESTANE; GONADORELIN DERIVATIVE; GOSERELIN; LETROZOLE; RALOXIFENE; RISEDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID;

AGE; ARTICLE; BODY MASS; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY MENOPAUSE; FAMILY HISTORY; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; MONOTHERAPY; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT;

EID: 36649025422     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.10.004     Document Type: Article

References (28)

1. NIH Consensus Development Panel. Osteoporosis prevention, diagnosis, and therapy. JAMA 285 (2001) 785-795
2. Kanis J.A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359 (2002) 1929-1936
3. World Health Organization. WHO technical report series 921: prevention and management of osteoporosis, World Health Organization, Geneva, Switzerland, 2003.
4. Sornay-Rendu E., Munoz F., Garnero P., Duboeuf F., and Delmas P.D. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 20 (2005) 1813-1819
5. Who are candidates for prevention and treatment for osteoporosis? Osteoporosis Int 1997;7:1-6.
6. Cummings S.R., Browner W.S., Bauer D., et al., Study of Osteoporotic Fractures Research Group. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 339 (1998) 733-738
7. Albrand G., Munoz F., Sornay-Rendu E., DuBoeuf F., and Delmas P.D. Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone 32 (2003) 78-85
8. Cummings S.R., Nevitt M.C., Browner W.S., et al., Study of Osteoporotic Fractures Research Group. Risk factors for hip fracture in white women. N Engl J Med 332 (1995) 767-773
9. Chen Z., Maricic M., Bassford T.L., et al. Fracture risk among breast cancer survivors. Results from the Women's Health Initiative Observational Study. Arch Intern Med 165 (2005) 552-558
10. Kanis J.A., McCloskey E.V., Powles T., Paterson A.H.G., Ashley S., and Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 79 (1999) 1179-1181
11. Shapiro C.L., Manola J., and Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19 (2001) 3306-3311
12. Greep N.C., Giuliano A.E., Hansen N.M., Taketani T., Wang H.-J., and Singer F.R. The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med 114 (2003) 653-659
13. Eastell R., Hannon R.A., Cuzick J., Dowsett M., Clack G., and Adams J.E. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21 (2006) 1215-1223
14. Coleman R.E. Effect of anastrozole on bone mineral density: 5-year results from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 24 Suppl. (2006) 5s [Abstract 511]
15. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
16. Coleman R.E., Banks L.M., Girgis S.I., et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8 (2007) 119-127
17. Thurlimann B., Keshaviah A., Coates A.S., et al., The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
18. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
19. Hadji P. Aromatase inhibitor-associated bone loss in breast cancer. Eur Oncol Dis 1 (2007) 35-38
20. Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
21. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042-4057
22. Siris E.S., Chen Y.-T., Abbott T.A., et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164 (2004) 1108-1112
23. Bundred N.J., Helmyr P., Kenemans P., et al. Incidence of osteoporosis in breast cancer patients-baseline data from the LIBERATE trial. Breast Cancer Res Treat 100 Suppl. 1 (2006) S112 [Abstract 2095]
24. Gnant M.F.X., Mlineritsch B., Luschin-Ebengreuth G., et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25 (2007) 820-828
25. Aapro M. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program. Breast 15 Suppl. 1 (2006) S30-S40
26. Brufsky A., Harker W.G., Beck J.T., et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25 (2007) 829-836
27. Brufsky A., Bundred N., Coleman R., et al. An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). Breast Cancer Res Treat 100 Suppl. 1 (2006) S25 [Abstract 107]
28. Brufsky A., Dong M., Lund K., et al. Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). Breast Cancer Res Treat 100 Suppl. 1 (2006) S233 [Abstract 5060]